Genetic Study of Nephrolithiasis in Gouty Diathesis

Gouty diathesis describes uric acid or calcium oxalate nephrolithiasis and low urinary pH (<5.5). A hereditary component has been outlined for several forms of nephrolithiasis (such as hypercalciuria, hyperoxaluria, cystinuria, renal tubular acidosis), leading to the hypothesis of a genetic predisposition to nephrolithiasis. At the Unit of Nephrology, Ospedali Riuniti di Bergamo, more than 100 patients affected by gouty diathesis are followed. Fifty percent of them has a familiarity for kidney stones formation. The aim of our study is to identify the genetic factors that predispose to the development of nephrolithiasis in patients with gouty diathesis.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

INTRODUCTION Nephrolithiasis is a common disorder with a reported incidence of 12% in industrialized countries. The peak incidence is in ages 20s to 40s. Men are affected two to three times more often than women. Gouty diathesis describes uric acid or calcium oxalate nephrolithiasis and low urinary pH (<5.5) in the absence of excessive gastrointestinal alkali loses or dietary animal protein excess. Hyperuricemia, hypertriglyceridemia, and a history of gouty arthritis may be present. Subjects with gout are singularly predisposed to stone formation. Persistent acidity of the urine is a common manifestation of primary gout, that may be accompanied by uric acid nephrolithiasis. In the presence of an increase in the concentration of uric acid in the urine, the formation of uric acid stones is further facilitated.

In the primary forms of nephrolithiasis the most important predisposing factors for kidney stones are: hypercalciuria, hyperoxaluria, hyperuricosuria, hypocitraturia, hypomagnesuria, high urinary sulfate, low urine volume, high urinary sodium, cystinuria, infection, persistently high or low urinary pH. A hereditary component has been outlined for several of these abnormalities, leading to the hypothesis of a genetic predisposition to nephrolithiasis. Pirastu and co-workers took advantage from a small, isolated population from Sardinia, characterized by a high prevalence of Uric Acid Nephrolithiasis (UAN). The disease shows familial clustering, although the transmission of UAN does not follow a simple mendelian inheritance pattern, suggesting that hereditary factors could play an important role in susceptibility to UAN. They found an association of UAN to a new gene, called ZNF365, and in particular to its variant Ala62Thr, making it a strong candidate predisposing factor.

At the Unit of Nephrology, Ospedali Riuniti di Bergamo, we follow at the moment 560 patients with nephrolithiasis of which more than 100 are affected by gouty diathesis. 50% of all patients with gouty diathesis has a familiarity for kidney stones formation.

Understanding of the genetic factors that contribute to the development of this disorder may lead to earlier diagnosis, thus allowing to identify, within a family, subjects that are at risk to develop nephrolithiasis before manifestation of the disease. These subjects may have access to counseling aimed at modifying their dietetic and sanitary attitudes and/or to pharmacological treatments in order to prevent the manifestation of the renal disease or to slow its progression.

AIM The study is aimed at identifying the genetic factors that predispose to the development of nephrolithiasis in patients with gouty diathesis.

DESIGN Fifteen consecutive unrelated patients with familial form of nephrolithiasis associated with gouty diathesis (at least two affected subjects within a family) will be recruited, within 3 years, through the stone clinic ambulatory of the Unit of Nephrology, Ospedali Riuniti di Bergamo.

All patients affected by gouty diathesis and their selected relatives will undergo to the following evaluations:

  • clinical history collection;
  • renal ultrasound examination, to confirm previous diagnoses and identify asymptomatic cases;
  • metabolic analyses, including:
  • blood collection in order to evaluate: urate, urea triglycerides, calcium, phosphate, creatinine, bicarbonate, sodium, potassium, chloride, glucose;
  • 24 hours urine collection in order to evaluate urate, calcium, phosphate, oxalate, citrate, urea, magnesium, sodium, chloride, creatinine, sulphate, ammonium; determination of urinary pH and titrable acidity; calculation of acid net excretion;
  • morning urine spot in order to evaluate volume, pH, calcium, uric acid, creatinine;
  • genetic analyses: 10 ml blood on EDTA to obtain DNA and 3 ml without anticoagulant to obtain serum from each subject will be collected.

Study Type

Observational

Enrollment (Actual)

37

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Bergamo
      • Ranica, Bergamo, Italy, 24020
        • Clinical Research Center for Rare Diseases

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 years to 85 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Unrelated patients with familial form of nephrolithiasis associated with gouty diathesis (at least two affected subjects within a family).

Description

Inclusion Criteria:

  • male and female, ≥ 10 years of age
  • uric acid or calcium oxalate nephrolithiasis
  • urinary 24 h pH < 5.5 in absence of high animal protein intake (urinary sulphate excretion <25 mM/24 h after one week of low animal protein intake)
  • familial history of kidney stones (at least two first or second degree family members affected)
  • written informed consent according to the Declaration of Helsinki guidelines

Exclusion Criteria:

  • renal colic in the 4 weeks preceding evaluations
  • excessive gastrointestinal alkali loses
  • inability to fully understand the purposes of the study or to provide a written informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Healthy subjects
Patients with gouthy diathesis

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Erica Daina, MD, Mario Negri Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2005

Primary Completion (Actual)

January 1, 2010

Study Completion (Actual)

May 1, 2010

Study Registration Dates

First Submitted

September 7, 2005

First Submitted That Met QC Criteria

September 7, 2005

First Posted (Estimate)

September 8, 2005

Study Record Updates

Last Update Posted (Actual)

April 4, 2023

Last Update Submitted That Met QC Criteria

March 31, 2023

Last Verified

October 1, 2009

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nephrolithiasis

Clinical Trials on Genetic analyses

3
Subscribe